Sionna Therapeutics to Cut 46% of Staff to Focus on Cystic Fibrosis Drug Development
By Elias SchisgallSionna Therapeutics will cut around 46% of its workforce to focus its resources on developing a cystic fibrosis treatment.The company said Monday that it will advance a combination of SION-451 and SION-2222 to a phase 2a proof-of-concept trial to treat cystic fibrosis. The layoffs…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.